Zhejiang Pharmaceutical launched the first phase I clinical study of arx788
-
Last Update: 2016-03-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Zhejiang medicine / ambrx company announced on March 21 to launch the first phase I clinical study of arx788 (anti HER2 monoclonal antibody ADC) The study will be conducted in multiple centers in Australia and New Zealand to assess the safety, tolerability and pharmacokinetics of arx788 Zhejiang Pharmaceutical has submitted arx788 clinical application to CFDA at the beginning of this year Zhejiang Pharmaceutical and ambrx reached a cooperation agreement on arx788 on June 14, 2013 Zhejiang Pharmaceutical has the commercial development right of arx788 in China, and ambrx reserves the commercial right of arx788 outside China Wuxi apptec has provided pre clinical research and production process development services of arx788 for Zhejiang medicine ARX788H is a monoclonal antibody, and is more specific and less toxic than simultaneous interpreting of ADC (antibody drug conjugates) Ambrx is an innovative biotechnology company with more than 700 patents in the world Its core competitiveness is protein drug development technology, such as protein site conjugation technology, non natural amino acid site insertion protein sequence technology Ambrx has cooperative relations with several international pharmaceutical giants, such as MSD, Merck (acquired the patent of arx424, a multiple sclerosis treatment drug under research in 2012, and will obtain the equity of ambrx), Lilly, Bristol Myers Squibb, etc
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
